Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Antigenicity Study of CFA-001, cefazolin, a cephalosperin Derivative Produced by an :Enzymatic Semisynthesis

  • Park, Jong-Il (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
  • Jeong, Tae-Cheon (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
  • Kim, Hyoung-Chin (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
  • Han, Sang-Seop (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
  • Roh, Jung-Koo (Toxicology Research Center, Korea Research Institute of Chemical Technology) ;
  • Kim, Jeong-Hwan (R&D Center, Cheil Jedang Inc.) ;
  • Jeon, Yeong-Joong (R&D Center, Cheil Jedang Inc.) ;
  • Kim, Dal-Hyun (R&D Center, Cheil Jedang Inc.) ;
  • Kim, Je-Hak (R&D Center, Cheil Jedang Inc.) ;
  • Park, Kwan-Ha (Department of Fish Pathology, Ocean Sciences and Technology, Kunsan National University)
  • Published : 1997.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

The antigenic potential of CFA-001, cefazolin, a cephalosporin derivative produced by an enzy-matic semisynthesis, was determined in Hartley guinea pigs. A battery of tests employed consisted of active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA), and indirect hemagglutination test (IHA). The results were as follows: 1) In ASA, no signs attributable to anaphylaxis was observed in guinea pigs sensitized with CFA-001, whereas OVA-sensitized animals induced severe anaphylactic symptoms; 2) guinea pigs did not produce antibodies against CFA-001 when sensitized with or without Freund's complete adjuvant (FCA) in homologous PCA tests. Meanwhile, antibodies against ovalbumin (OVA) were clearly detected; 3) No CFA-001-specific hemagglutination was observed in the IHA using sera obtained from CFA-001- sensitized guinea pigs. These results suggest that CFA-001 has no antigenicity potential in guinea pigs.

Keywords